SOPHiA GENETICS (SOPH) CTO sells 5,000 shares in Rule 10b5-1 trading plan
Rhea-AI Filing Summary
SOPHiA GENETICS SA Chief Technology Officer Abhimanyu Verma reported a sale of 5,000 Ordinary Shares of SOPH on 2026-08-07 at $7.60 per share in an open market or private transaction. After this transaction, he directly holds 182,171 Ordinary Shares. The sale was made pursuant to a duly adopted Rule 10b5-1(c) trading plan.
Positive
- None.
Negative
- None.
Insider Trade Summary 10b5-1
Net Seller: 5,000 shares
Net Sell
1 txn
Insider
Verma Abhimanyu
Role
Chief Technology Officer
Sold
5,000 shs ($38K)
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Sale | Ordinary Shares F1 | 5,000 | $7.60 | $38K |
Holdings After Transaction:
Ordinary Shares — 182,171 shares (Direct)
Footnotes (1)
- F1. Transaction made pursuant to duly adopted trading plan under Rule 10b5-1(c).
Key Figures
Shares sold: 5,000 Ordinary Shares
Sale price: $7.60 per share
Shares held after transaction: 182,171 Ordinary Shares
3 metrics
Shares sold
5,000 Ordinary Shares
Sale by CTO Abhimanyu Verma on 2026-08-07
Sale price
$7.60 per share
Price for the 5,000-share sale on 2026-08-07
Shares held after transaction
182,171 Ordinary Shares
Direct holdings of Abhimanyu Verma following the sale
Key Terms
Ordinary Shares, Rule 10b5-1(c), trading plan
3 terms
Rule 10b5-1(c) regulatory
"Transaction made pursuant to duly adopted trading plan under Rule 10b5-1(c)."
Rule 10b5-1(c) is an SEC guideline that lets company insiders set up a written, pre-planned schedule to buy or sell their company stock when they are not in possession of material, nonpublic information. For investors, it matters because such plans can reduce the appearance of insider trading by separating decisions from inside knowledge—like putting your trades on autopilot—while also requiring scrutiny since pre-planned trades can still affect market confidence and share value.
trading plan financial
"Transaction made pursuant to duly adopted trading plan under Rule 10b5-1(c)."
A trading plan is a written set of rules an investor follows about what to buy or sell, when to enter and exit positions, and how much risk to accept—like a travel itinerary that maps the route, stops, and budget before a trip. It matters because it helps remove emotional decisions during market swings, enforces discipline, and makes performance easier to review and improve, reducing the chance of costly impulsive moves.
AI-generated analysis. How Rhea-AI works. Not financial advice.
FAQ
What insider transaction did SOPHiA GENETICS (SOPH) report for Abhimanyu Verma?
SOPHiA GENETICS reported that CTO Abhimanyu Verma sold 5,000 Ordinary Shares of SOPH on 2026-08-07 at $7.60 per share, in an open market or private transaction under a Rule 10b5-1(c) trading plan.
Was the SOPHiA GENETICS (SOPH) insider sale made under a Rule 10b5-1 trading plan?
Yes. The filing notes the sale was made pursuant to a duly adopted Rule 10b5-1(c) trading plan. This indicates the 5,000-share sale at $7.60 was executed according to a pre-established trading arrangement.
What role does Abhimanyu Verma hold at SOPHiA GENETICS (SOPH) in this Form 4?
In this Form 4, Abhimanyu Verma is identified as the Chief Technology Officer of SOPHiA GENETICS SA. The reported transaction covers his personal direct holdings of Ordinary Shares, including the 5,000-share sale and the 182,171 shares remaining.
Is the SOPHiA GENETICS (SOPH) insider sale categorized as direct or indirect ownership?
The sale is categorized as direct ownership. After selling 5,000 Ordinary Shares at $7.60, Abhimanyu Verma’s remaining 182,171 shares are also reported as directly held, with no intermediary entity indicated.